Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: Time to progression and survival

Breast Cancer

Volumn 15, Issue 1, 2008, Pages 57-64

  Nishimura, Reiki ^a   Okumura, Yasuhiro ^a   Arima, Nobuyuki ^a  

^a KUMAMOTO CITY HOSPITAL   (Japan)

Author keywords

Breast cancer; HER2 status; Prognosis; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DRUG COMBINATION; FEMALE; GENETICS; HUMAN; MIDDLE AGED; MORTALITY; PROTO ONCOGENE; SURVIVAL; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GENES, ERBB-2; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS;

EID: 43149110184     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-007-0014-z     Document Type: Conference Paper

References (26)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science 1987;235(4785):177-82. (Pubitemid 17231334)
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707- 12. (Pubitemid 19147683)
3. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 2001;12(suppl 1):S3-S8. (Pubitemid 32750577)
4. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198(2-3):165-84.
5. Pauletti G, Godolphin W, Press MF, et al. Detection and quantization of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13(1):63-72. (Pubitemid 26248546)
6. Hynes NE, Gerber HA, Saurer S, et al. Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J Cell Biochem 1989;39(2):167-73. (Pubitemid 19062782)
7. Hynes NE. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 1994;4(1):19-26.
8. Di Leo A, Larsimont D, Beauduin M, et al. CMF or anthracycline- based adjuvant chemotherapy for node-positive breast cancer patients: 4 year results of a Belgian randomized clinical trial with predictive markers analysis. Proc Am Soc Clin Oncol 1999;18:69a (abstract 258).
9. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer: International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:1049-56.
10. Ravdin PM. Prognostic factors in breast cancer In: Perry MC (eds) 1997 ASCO Educational Book. Alexandria: American Society of Clinical Oncology; 1997, pp. 217-27.
11. Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a southwest oncology group study. Clin Cancer Res 1998;4:7-12. (Pubitemid 28062871)
12. Dieras V, de Cremoux D, Le Doussal V, et al. Is erbB-2 a predictive marker for response to primary chemotherapy (CT) for operable breast cancer? Prospective study in a phase III randomized, parallel study of doxorubicin/cyclophosphamide (AC) and doxorubicin/Taxol1 (paclitaxel) (AT). Proc Am Soc Clin Oncol 1999;18:85a (abstract 322).
13. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptornegative breast cancer. J Natl Cancer Inst 1998;90(18):1361-70. (Pubitemid 28439960)
14. Petit T, Ghnassia JP, Rodier JF, et al. Relationship between erbB- 2 status and neoadjuvant chemotherapy response is dependent on anthracycline dose intensity. Proc Am Soc Clin Oncol 2000;19:96a (abstract 370).
15. Ravdin PM, Green S, Albain KS, et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone. Proc Am Soc Clin Oncol 1998;17:97a (abstract 374).
16. Untch M, Thomssen C, Kahlert D, et al. Lack of c-erbB-2 overexpression predicts better response to dose intensification of anthracycline-based chemotherapy in high-risk breast cancer. Breast Cancer Res Treat 1998;50:238 (abstract 110).
17. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96(10):739-49. (Pubitemid 38771819)
18. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18(13):2241-51. (Pubitemid 29186925)
19. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26. (Pubitemid 34111379)
20. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48. (Pubitemid 29415219)
21. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
22. Marty M, Cognetti F, Maraninchi D, et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as firstline treatment: the M77001 study group. J Clin Oncol 2005;232:4265-74. (Pubitemid 46207001)
23. Pegram M. Docetaxel and herceptin: foundation for future strategies. Oncologist 2001;6:22-5. (Pubitemid 32423182)
24. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001;61(Suppl 2):14-21. (Pubitemid 33033420)
25. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl Med 2005;353:1673-84. (Pubitemid 41464706)
26. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72. (Pubitemid 41464705)